HLB shares plunge to the lower price limit after FDA requests supplements for liver cancer drug
HLB recorded an intraday fall to the lower price limit after news in 7month 10day that the U.S. Food and Drug Administration (FDA) had requested supplemental clinical data, and a sharp decline in shares of companies in the same group continued. During the same period, news also emerged that Emart’s target price had been lowered by 15%, along with a tally showing that, including leveraged products, 83% of stock-market trading value was concentrated in certain stocks.
HLB 7month 10day fell to the lower price limit intraday immediately after disclosing the FDA’s request for supplements related to its liver cancer drug. Investors closely watched the disclosure and the simultaneous sharp decline in the share prices of its affiliates.
Reports continued to emerge that many HLB affiliates had recorded falls to the lower price limit on the same day. Several affiliates maintained steep declines until before the market close.
The FDA was reported to have requested additional supplements to some of the clinical data related to HLB’s liver cancer drug under development. The company is proceeding with the related procedures and subsequent disclosures.
7 month 9on the day, some securities firms lowered Emart’s price target by 15%. Starbucks’ weak sales were cited as a reason for the adjustment, and the impact on Emart’s performance was discussed.
Across the market, estimates showed that, including leveraged products, 83% of stock-market trading value was concentrated in certain large-cap stocks. The concentration of trading value indicates that investor attention is narrowly focused.
This series of news reports was concentrated between 7 month 9~10 days. It is necessary to monitor additional disclosures from the companies involved and the stock-market response.
The key facts confirmed so far are the company’s disclosure requesting supplementation, the occurrence of a limit-down in an affiliated stock, the cut to Emart’s price target, and the trading-value concentration figure. The details may change if the companies issue additional official disclosures.
Investors should check the company’s additional disclosures and regular reports.